CCM
Camber Capital Management Portfolio holdings
AUM
$718M
1-Year Return
4.23%
This Quarter Return
-2.44%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$1.71B
AUM Growth
-$12.9M
(-0.75%)
Cap. Flow
+$64.3M
Cap. Flow
% of AUM
3.76%
Top 10 Holdings %
Top 10 Hldgs %
63.62%
Holding
35
New
7
Increased
9
Reduced
6
Closed
6
Top Buys
| 1 |
HCA Healthcare
HCA
|
$81.1M |
| 2 |
Gilead Sciences
GILD
|
$67.6M |
| 3 |
Viatris
VTRS
|
$66.6M |
| 4 |
United Therapeutics
UTHR
|
$28.7M |
| 5 |
DaVita
DVA
|
$28.1M |
Top Sells
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$95.3M |
| 2 |
Biogen
BIIB
|
$94.6M |
| 3 |
NUVA
NuVasive, Inc.
NUVA
|
$42.6M |
| 4 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$37.2M |
| 5 |
MDCO
Medicines Co
MDCO
|
$28.1M |
Sector Composition
| 1 | Healthcare | 94.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sutro Biopharma
STRO
$89.9M
| $6.83M | 0.32% |
600,000
| – | – |
|
27
Alkermes
ALKS
$4.94B
| $4.24M | 0.2% |
+188,281
| New | +$4.24M |
|
28
Surgery Partners
SGRY
$2.89B
| $1.3M | 0.06% |
160,084
| – | – |
|
|
29
Biogen
BIIB
$20.6B
| – | – |
-400,000
| Closed | -$94.6M |
|
30
SPDR S&P 500 ETF Trust
SPY
$660B
| – | – |
0
| – | – |
|
|
EGRX
31
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| – | – |
-291,600
| Closed | -$14.7M |
|
|
NUVA
32
DELISTED
NuVasive, Inc.
NUVA
| – | – |
-750,000
| Closed | -$42.6M |
|
|
CLVS
33
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-1,500,000
| Closed | -$37.2M |
|
|
GBT
34
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-1,800,000
| Closed | -$95.3M |
|
|
ELGX
35
DELISTED
Endologix Inc
ELGX
| – | – |
-930,001
| Closed | -$6.15M |
|